CytoDyn (CYDY) Amortization - Deferred Charges (2015)
CytoDyn (CYDY) posted Amortization - Deferred Charges of $219000.0 for Q2 2015.
CytoDyn (CYDY) Amortization - Deferred Charges (2015) Analysis & Trends
CytoDyn's Amortization - Deferred Charges history runs 1 years deep, the most recent figure standing at $219000.0 for Q2 2015.
- Quarterly Amortization - Deferred Charges changed N/A year-over-year to $219000.0 in Q2 2015, while the trailing twelve-month figure through May 2015 was $219000.0 (changed N/A YoY) and the FY2015 annual result came in at $219000.0, changed N/A from the prior year.
- Amortization - Deferred Charges was $219000.0 for Q2 2015 at CytoDyn.
- Across five years, Amortization - Deferred Charges topped out at $219000.0 in Q2 2015 and bottomed at $219000.0 in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytoDyn | 267.79 Mn | 267.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2015 | 219,000.00 |
| May 31, 2015 | 219,000.00 |